Asahi Kasei Pharma became the latest to join a growing list of drug makers partnering with PeptiDream, a spin-out of the University of Tokyo, to discover macrocyclic and constrained peptides against multiple targets. Under their collaboration deal announced on March…
To read the full story
Related Article
- PeptiDream Hits Milestone with Asahi Kasei Collaboration
December 10, 2025
BUSINESS
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…





